The new site will manufacture highly active compounds, immunosuppresive drugs, sensitizing agents, and controlled drugs. Dosage forms available include high and multiple doses, combination products, multiple release and fixed dose.
According to the CDMO, the facility will also provide “gateway services” into Japan, including inspection, packaging, and testing for highly potent oral solid drugs and sterile injectables made by the company outside the country.
The company will also provide inspection and packaging services for drugs manufactured at the Japan facility and will also offer services such as cold-chain handling and market testing for release to the Japanese market.
Earlier this year, Pfizer CentreOne also expanded its fill-finish and highly potent solid oral dose service offerings at two of its contract manufacturing facilities in the US and Ireland. Pete Stevenson, Pfizer CentreOne vice president and general manager told us at the time that the company would be growing to meet the needs of its biopharmaceutical partners.